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Consumer genomics and mobile health provide health-related information to individuals and offer advice for
lifestyle change. These ‘technologies for healthy lifestyle’ occupy an ambiguous space between the highly regu-
lated medical domain and the less regulated consumer market. We argue that this ambiguity challenges implicit
distinctions between what is medical and what is related to personal lifestyle choices within current regulatory
systems. In this article, we discuss how consumer genomics and mobile health devices give rise to new ways of
creating (and making sense of) health-related knowledge. We also address some of the implications of
harnessing, rather than denying, the hybridity of mobile health devices, being situated between medical devices
and consumer products, between health and lifestyle.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
While genomics has traditionally been associated with reductionist
approaches to health and disease, other newer 'omics symbolise inter-
connectedness and complexity (Meloni and Testa, 2014; Prainsack
et al., 2014). Epigenomics in particular, by exploring how environmen-
tal stimuli ‘mark’ and alter the regulation of genes, emphasises the
importance of behavioural factors for health. This resonates with the
thrust of public health campaigns, for which behaviour change is an
important way to increase health. National and international organisa-
tions devoted to the promotion of public health have highlighted the
importance of behavioural change to improve wellbeing and preven-
tion of disease (WHO, 2002, 2008; IUHPE 2002; Department of Health,
2004).1 Central assumptions in these programmes are that people
have the power to choose healthy or unhealthy lifestyles, and that
they are thus at least partly accountable for their health (Buyx and
Prainsack, 2012).
Perhaps unsurprisingly in this context, healthy living, or healthy
lifestyle,2 has become central to the commercialisation of consumer
products as well. As Sarah Nettleton put it, “lifestyle is a concept
which has come to refer to people's styles of living, which, in turn, are
shaped by their patters of consumption” (Nettleton, 2013).3 The
commercialisation of consumer goods with remedial qualities4 has
been seen to symbolise the rise of a new petite bourgeois culture
of healthy lifestyles, in which people are seen as consumers
(Featherstone, 1991). There is no area of research, it seems, that is not
used for commercialisation of ‘personalised’ services to consumers:
companies offer personalised health and diet recommendations on the
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1 See also the amount of informative material on how to change eating and ﬁtness
habits, offered by the Weight control Information Network (WIN) an information centre
of the National Institute for Diabetes and Digestive and Kidney Diseases at the US
Department of Health and Human Services: http://www.win.niddk.nih.gov/publications/
[Accessed on 6th January 2015].
2 For a sociological perspective on concept(s) of lifestyle, philosophies of wellbeing and
health promotion schemes, see O'Brien (1995). In this essay, the author shows how the
concept of lifestyle, initially referred to individual choices, has increasingly been used as
a “vehicle for differentiating a population” (193) in a consumerist and market oriented
culture. The association between health and lifestyle has, according to O'Brian, been a po-
litical construction together with the emergent role of the concept of “wellbeing” in health
promotion strategies.
3 The Oxford English Dictionary (OED) deﬁnes “lifestyle” as a “style or way of living
(associated with an individual person, a society, etc.); esp. the characteristic manner in
which a person lives (or chooses to live) his or her life.” The OED deﬁnition of compounds
such as “lifestyle advice”, “lifestyle change”, “lifestyle factor”, etc., recites “Of or relating to
theway inwhich one lives (or chooses to live) one's life, esp.with regard to quality of life”.
http://www.oed.com/view/Entry/108129?redirectedFrom=lifestyle#eid [Accessed on
December 1st, 2014].
4 See Tomes (2001) for a history of consumer culture and its relationshipwithmedicine
in the period 1900–1940.
http://dx.doi.org/10.1016/j.atg.2015.02.001
2212-0661/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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basis of the microorganisms inhabiting their bodies,5 on their blood
type,6 or on their DNA.7
Genomics has been a particularly active playground for personalised
services marketed directly to consumers. For example, in the years
2000–2010 a plethora of companies offering so-called direct-to-
consumer (DTC) genetic testing entered themarket, providing informa-
tion about genetic predisposition to diseases and traits (Prainsack et al.,
2008; Kalokairinou et al., 2014). Many of them also offered advice on
lifestyle changes. As pointed out by Saukko et al. (2010) for the case of
nutrigenetic testing, lifestyle products have emerged as an alternative
regulatory category to medical genetic tests. According to the authors,
the label of ‘lifestyle products’ has been advanced by scientists who,
while legitimizing the ‘seriousness’ of these tests, negotiated the space
for a “hybrid or compromise category” that would stand “between
medicine and consumer culture” (Saukko et al., 2010:751).
A renegotiation of the boundaries between medical and lifestyle
products can be seen also in other areas. Digital mobile devices increas-
ingly leave the gadgetworld to enter themedical domain. These devices
include wearable sensors for the tracking of movements or physiologi-
cal functions, mobile applications (‘apps’) for the calculation and analy-
sis of caloric intake, or for monitoring sleep patterns and offering
personalised advice. These products are marketed as tools to enable
users to eat healthier, move more and become aware of ‘sustainable’
lifestyles. Initially appeared on the market as consumer products,
these devices are increasingly being co-opted into the medical domain.
Policy makers regard these products as having “the potential to play a
part in the transformation of healthcare and increase its quality and ef-
ﬁciency” (EC, 2014: 3) while insurance companies consider scenarios
wherein these devices can be used to monitor their customers' lifestyle
to ultimately adapt their premium.8 These innovations occupy the am-
biguous space between the highly regulated medical domain and the
less regulated consumer market, where pre-market approval is easier
to obtain and integration in the clinical pathway through public pro-
curement is not required.
This ambiguous status of m-health devices and applications chal-
lenges the intuitive distinction betweenwhat is medical andwhat is in-
stead related to personal lifestyle choices. In the following section we
will show how regulatory questions raised by what we call ‘technolo-
gies for healthy lifestyle’, such as DTC genomics and m-health, signify
a blurring of institutionally established normative categories. We will
then reﬂect on how m-health devices and apps change the meanings
of health information and propose new ways of creating (and making
sense of) knowledge. Finally, we will address questions related to the
blurring of the distinction of lifestyle v. medicine that are helpful for
policy making.
2. Regulatory challenges and controversies
Technologies challenge established social values andmeanings. Take
the example of brain-machine interfaces and how, by blurring the dis-
tinction between physical bodies, minds and machines they question
our deﬁnition of ‘body’ and ‘person’ (Lucivero and Tamburrini, 2007).
Swierstra and colleagues9 argue that new technologies destabilise con-
cepts that serve as a guide to classify reality, and that they create new
interpretations (Swierstra et al., 2009: p 276). By doing so, new technol-
ogies challenge our symbolic order, that is, the grid of concepts that are
used in a certain society to order and categorise reality. Changingmean-
ings in turn raise new normative questions. This has happened in con-
nection with molecular medicine, for example, which presented us to
the idea that it is possible to be sick at the molecular level without the
patients' experience of symptoms and introduced the concept of ‘bio-
markers’ (Boenink, 2009). The latter shift challenges deﬁnitions of
‘healthy individuals’ vs. ‘patients’ (as subjects suffering from a symptom
or disease) and requires healthcare systems to adapt to this new
framework.10 As the concepts of ‘healthy’ and ‘sick’, also the labels of
‘medical’ vs. ‘lifestyle-related’ can be considered a dichotomy that
seems to be assumed in European and North American regulatory
tools. The unfolding regulatory debate around DTC genetic testing and
m-health, described below, shows that new technologies for health
andwellbeing present a hybrid character that destabilises some norma-
tive categories referring to the medical v. lifestyle-related distinction.
2.1. Direct-to-consumer genetic testing
In autumn 2007, two companies started offering online tests which
would soon become a concern of health authorities and policy makers:
23andMe in Mountain View, CA, and the Icelandic company deCODE
Genetics, offered individual genetic risk calculations for fees starting at
a few hundred dollars. Customers could purchase a ‘spit kit’ directly
from the company, post it and, only fewweeks later, access their genetic
risk scores for a wide range of diseases, drug metabolism, and other
characteristics. Other companies soon followed suit; a few weeks after
23andMe and deCODE Genetics,Navigenics (Foster city, CA) started offer-
ing a similar service; and in 2009, San Diego-based Pathway Genomics
became the fourth Personal Genomics (PG) company to offer SNP-
based11 genome-wide risk predictions to consumers online. With the
exception of Navigenics, which restricted the scope of their tests to im-
portant health conditions from the beginning, these companies offered
‘personalised’ risk calculations for a wide range of phenotypes and traits
(e.g. diabetes, alcohol ﬂush syndrome, eye colour), as well as results of
SNP-based analysis of carrier status and drug response.12
Only a fewmonths after these online serviceswere set up, health au-
thorities stepped in. During spring and summer 2008, the Department
of Health of the state of New York and the California Department of
Public Health sent letters to 23andMe and Navigenics warning them of
continuing to offer their services over the Internet without a genetic
testing licence. Companies insisted that their legislation and regulation
for clinical genetic testing should not apply to them, as their services did
not intend to give medical information, but that they merely sought to
educate and entertain their customers (see Prainsack, 2011). At the
same time, however, these companies also made sure that they com-
plied with relevant legal provisions—whichmeant that licensed physi-
cians had to ‘order’13 the PG test, and DNA analysis had to be carried out
in especially accredited laboratories. In the US, conﬂicts with regulators
have since then continued, and reached a new peak at the end of 2013,
when the US Food and Drug Administration (FDA) ordered 23andMe to
5 http://ubiome.com/#how-it-works (Accessed on January 6th 2015).
6 http://www.dadamo.com/.
7 http://mydietclinic.com/services/nutrigenomix-testing/ (Accessed on January 6th
2015).
8 Such insurance policies are currently explored in Europe by the Generali Group that,
within the next 12 to 18 months, plans to offer policies that reward healthy people, based
on the information provided by their tracking devices (http://www.sueddeutsche.de/
news/wirtschaft/versicherungen-versicherer-generali-will-ﬁtnessdaten-von-kunden-
sammeln-dpa.urn-newsml-dpa-com-20090101-141121-99-02990 [Accessed on January
6, 2015]).
9 In their article, the authors build on the concept of ‘symbolic order’ elaborated by an-
thropologist Mary Douglas (Douglas, 1966) and on the idea of technologies as ‘monsters’
discussed in Smits, 2006.
10 Similarly, the concept of ‘patients in waiting’ proposed by Timmermans and
Buchbinder (2010) captures the liminality of patients involved in screening trajectories
that place them in a category in between normal health and pathology.
11 Single nucleotide polymorphisms (SNP) are variations in theDNA at the level of single
bases (nucleotides: A, T, C, and G).
12 While people celebrated this development as a new era of patient empowerment and
the democraticisation of medicine, others were concerned about the questionable robust-
ness of the scientiﬁc evidence underpinning personalised risk calculations (e.g. Janssens
et al., 2008), or about the fact that these companies cut out medical professionals; in the
early days of personal genomics tests online, companies operated according to the ‘pure’
direct-to-consumer model (Prainsack and Vayena, 2013), and commentators were con-
cerned that lay peoplewouldnot be able to understand the probabilistic information given
to them by the companies (e.g. Hunter et al., 2008).
13 In practice the physicians only needed to sign off the order, without ever having met
with the test-taking person; see also Dvoskin and Kaufman, 2011.
45F. Lucivero, B. Prainsack / Applied & Translational Genomics 4 (2015) 44–49
stop offering health-related genetic risk information to new customers
(Herper, 2013). The company complied with this, but kept health-
related information visible to existing customers, and also accepted
new clients to whom they disclosed only information on genetic ances-
try which were not within the remit of the FDA. Although 23andMe
ceased to show the link between the SNP data and health risk informa-
tion, almost overnight, a number of apps and services emerged that
analysedpeople's SNP data— that the company enabled their customers
to download – for health-related genetic probabilities. 23andMe re-
sumed the disclosure of health-related risk calculations from the UK in
autumn 2014 (Gibbs, 2014).
In Europe, where PG testing is far lesswell known than in theUS, ge-
netic tests for medical usemust be ordered, and results received by, a li-
censed physician. This is the case in Austria and Germany, for example;
a difﬁculty regarding the interpretation of these laws lies in delineating
what tests are medical and which ones are not medical. Some tests are
clearly medical, e.g. when they look for a genetic variant that robustly
correlates with a disease; however such robust correlations do not
exist with many of the tests that companies such as 23andMe perform.
Similarly, within the EU, genetic tests are considered in vitro diagnostic
medical devices if they are health-related (Directive 98/79 European
Parliament and Council, 1998; see also Kalokairinou et al., in press). Ac-
cording to ongoing discussions on a draft regulation on medical
devices,14 there is a need to intensify scrutiny of these tests, mandate
the inclusion of healthcare professionals in the testing process, and in-
clude awider rangewithin the remit of the Regulation. The implications
would be that any genetic test that provides ‘information with direct or
indirect impact on health’ would be included in such Regulation
(European Commission, 2012; European Parliament, 2013; see
Kalokairinou et al., in press). This proposed framework does not seem
to entirely solve the controversy. In fact, the existing ambiguity regard-
ing ‘health-related tests’ would remain, as any genetic test can provide
information with at least indirect impact on health if we interpret ‘im-
pact’ widely.
2.2. Mobile health
According to a recent study, 97,000mobile health apps are currently
available, and it is predicted that themarketwill reach a value of $26bil-
lion in 2017 (Research2guidance, 2013). In April 2014, the European
Commission (EC) issued aGreen Paper onmobile health. This document
was accompanied by a staff-working document describing the “existing
EU legal framework applicable to lifestyle and wellbeing apps”. In this
document, the deﬁnition of m-health draws on a 2011 report of the
World Health Organization, according towhichm-health as component
of electronic health (eHealth) consisting of “medical and public health
practice supported by mobile devices, such as mobile phones, patient
monitoring devices, personal digital assistants (PDAs) and other wire-
less devices” (WHO, 2011: 6). Building on this deﬁnition the EC Green
Paper speciﬁed thatmobile health “also includes applications (hereafter
“apps”) such as lifestyle and wellbeing apps” (EC, 2014: 3)15 that is
“apps intended to directly or indirectlymaintain or improve healthy be-
haviours, quality of life andwellbeing of individuals” (ibidem). This def-
inition includes medication reminders for chronic patients, apps
offering ﬁtness or dietary recommendation and sensors “collecting
physiological, lifestyle, daily activity and environmental data” (ibidem).
In the Green Paper and related working staff document several reg-
ulatory and ethical challenges are addressed: the right to privacy and
data protection, the applicable EU legal framework for quality control
and certiﬁcation, patient safety, applicable reimbursement models, lia-
bility issues, interoperability, possibilities for international cooperation
and market potential, privacy, trust, disappointment and equal access.
Someof these challenges seem to be strictly connected to thedouble na-
ture of m-health as systems supporting both health practices and
lifestyle/wellbeing-related behaviours. This emerges speciﬁcally in the
section of the Green Paper that discusses the applicable EU legal frame-
work to ensure the development and safe adoption of these products. As
explained in the document, in the European Union, “there are no bind-
ing rules as to the delimitation between lifestyle andwellbeing apps and
a medical device or in vitro diagnostic medical device” (EC, 2014: 11).
The aforementionedMedical Devices Directive (MEDDEV)16 and the
in vitro diagnostic medical devices Directive,17 both currently under re-
vision to become Regulations,18 suggest that the “intended purpose” is a
criterion to establish whether products fall under the deﬁnition of a
(in vitro diagnostic) medical device and consequently establish wheth-
er theMEDDEV framework applies.WhenMEDDEV does not apply, it is
unclear what rules wellbeing and lifestyle apps have to comply with. To
complicate things, as discussed above, during the drafting of the
MEDDEV Regulation, the possibility of including the principle of “indi-
rect medical purpose” to the deﬁnition of medical devices has been de-
bated. This principle would prevent to leave the decision of the purpose
to the subjective intention of the manufacturer and would expand the
scope of the medical device regulation (Vollebregt 2014).
In the U.S., the FDA published some guidelines (2013) on how they
intend to approach the regulation of mobile medical applications. Ac-
cording to this early guidance, the FDA intends to use a risk-based ap-
proach and only regulate apps that “are intended to be used as an
accessory to a regulated medical device, or transform amobile platform
into a regulatedmedical device”.19 Therefore, many health apps that are
seen to present onlyminimum risk are not expected to be subject of fu-
ture regulation. Speciﬁcally, “health and wellness records (e.g. diet and
weight logs) for consumers are not being considered for regulation”
(Barton, 2012: p 2) because they are not expected to cause harm to
users.20 Within this regulatory uncertainty, some app developers have
decided to have their system go though the clearance process for med-
ical devices. WellDoc, for example, is a web-based mobile platform for
management of diabetes that “has introduced the ﬁrst mobile prescrip-
tion therapy for adults with type 2 diabetes-BlueStar” in June 2013.21
This app, whose developers ﬁled and received FDA clearance (Iyer,
2014), offers a piece of software that has to be prescribed by the health
14 See the reference to the MEDDEV draft regulation below.
15 TheWHO report is based on a survey conducted by theGlobal Observatory for eHealth
in 2009 and completed in 119member states. This survey contained a section dedicated to
m-health and including fourteen categories of m-health services such as: health call cen-
tres, emergency toll-free telephone services, managing emergencies and disasters, mobile
telemedicine, appointment reminders, community mobilization and health promotion,
treatment compliance, mobile patient records, information access, patient monitoring,
health surveys and data collection, surveillance, health awareness raising, and decision
support systems (WHO, 2011: 12). It is a sign of the times (the survey is from 2009) that
“apps” and Internet-based services on smart phones are not explicitly referred to in the
report.
16 Directive 93/42/EEC on medical devices.
17 Directive 98/79/EC on in vitro diagnostic medical devices.
18 In EU law, the difference between a directive and a regulation is that member states
have more leeway in deciding how to implement a directive, while a regulation immedi-
ately becomes a nationally enforceable law (i.e. regulations are self-executing).
19 Source: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/
ConnectedHealth/MobileMedicalApplications/ucm255978.htm#c [Accessed on Janu-
ary 6, 2015].
20 On January 20, 2015, after the submission of this article, the Centre for Devices and Ra-
diological Health released a Draft Guidance for Industry and FDA staff clarifying the differ-
ence between “low risk general wellness products” and regulatedmedical devices: “CDRH
deﬁnes general wellness products as products that meet the following two factors: (1) are
intended for only general wellness use, as deﬁned in this guidance, and (2) present a very
low risk to users' safety. Generalwellness productsmay include exercise equipment, audio
recordings, video games, software programs and other products that are commonly,
though not exclusively, available from retail establishments (including online retailers
and distributors that offer software to be directly downloaded), when consistent with
the two factors above”. Source: http://www.fda.gov/downloads/MedicalDevices/
DeviceRegulationandGuidance/GuidanceDocuments/UCM429674.pdf [Accessed on
January 30, 2015].
21 Source: https://www.bluestardiabetes.com/ [Accessed on January 6, 2015].
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provider and it will eventually be reimbursed by insurance providers as
pharmaceutical diabetes treatments.
The ambivalent status of m-health applications, being situated be-
tween medical devices and consumer products, raises challenges relat-
ed to certiﬁcation and quality control, reimbursement, liability, and data
protection.22 Moreover, the place of these applications in mainstream
healthcare pathways is unclear. Legislators face the dilemma of either
treating these products as non-medical devices — with the associated
risks for consumers' safety and the non-adoption of these solutions in
mainstream healthcare — or regulating them as medical devices —
with the risk of unsustainable costs for this growing market of small
and medium enterprises.
We argue, however, that this dichotomy can be surpassed, and that
important lessons can be learned from the case of consumer genomics.
Both consumer genomics andm-health raise questions concerning their
regulatory status. Both have in common that they do not neatly ﬁt into
existing categories that legal and regulatory systems operate with. On
the one hand, they differ frommedical devices in that their direct clini-
cal utility is often low. This is the case because the speciﬁcity and sensi-
tivity of the test is very low, because they test phenotypes that are not
directly clinically relevant, or because the data are not validated. Anoth-
er important difference between technologies for healthy lifestyle and
medical devices resides in the low risk for users' safety attributed to
the ﬁrst in comparison with the latter. On the other hand, the fact that
they can be used for healthcare intervention— e.g. by awoman consult-
ing her physician with a fertility issue bringing a several years of men-
strual cycle data on a handheld device, or by a person informing her
doctor that she may be a non-responder to certain blood-thinners fol-
lowing a consumer genomics test— raises issues about quality control;
if such data are used in a clinical context and they need to be accurate.23
Rather than force them into existing categories, regulation should ac-
knowledge that these products are hybrids between consumer and
medical products and embrace, instead of reject the nature of their nor-
mative ambiguity. In the following we make a ﬁrst step towards
harnessing such ambiguity by looking at the way these devices chal-
lenge our way to make sense of medical knowledge and health
information.
3. Changing meanings of medical information and expertise
Social scientists have shown that health information is never
intermediated by technologies in a simple, straightforward way, but al-
ways “mediated” (Latour, 2005) in complex and unpredictable ways:
“produced, distributed, regulated and used” via people, technologies,
places (Wathen et al., 2008: p.3). This implies that in order to
understand how devices for health and wellbeing challenge a society's
normative framework, it is important not only to look at regulatory un-
certainties, but also at how information is represented and understood
in practices of use.
3.1. DTC genomics
As one of us argued in the 2008, when several genome-wide online
testing services had just entered the market at the same time, regulatory
authorities were accustomed to assume that a medical test is a distinct
entity governed by a clearly discernible set of experts: doctors and
public-health authorities. This no longer holds true. Genomics blurs the
boundaries that make such clear distinctions possible. A genome scan re-
veals information that ismedical, genealogical and recreational. And those
who scan and interpret the data are not distinct bodies of experts, but in-
stead, novel conﬁgurations of geneticists, customers, ethicists, bioinfor-
matics experts and newmedia executives (Prainsack et al., 2008: 34).
The blurring of the boundaries between health-related information
and information about other factors, such as hair curl or alcohol ﬂush
syndrome, stems from the fact that our genomes inevitably contains in-
formation on other aspects than only our health. While clinical genetic
testing had ﬁltered out the answers to speciﬁc clinically relevant ques-
tions from the ‘noise’ of the genome, personal genome-wide testing on-
line contains information on any markers that had ever been studied,
health-related or not. Some companies offering genome-wide tests on-
line— such as bio.logis (bio.logis.com) based in Frankfurt, DE— restrict
their analyses to clinically useful and actionable information (Vayena
and Prainsack, 2013); others, such as 23andMe, disclose anything that
can be learned from genomic information, pertaining to health, ances-
try, and other traits such as intelligence or skin colour. People use and
make sense of this information sometimes, alone, sometimes with
friends and family members, or even with their physicians.24 Also the
use of this information can thus be health-related or not, depending
on the meaning and utility that users attribute to this information.
This is one of the most impactful ways in which online genetic testing
has challenged existing categories and boundaries: it moved a practice
to which clinicians had been the gate keepers – namely genetic testing
that provided health-relevant information — to situations where clini-
cians were involved only marginally, or not at all.25
3.2. m-Health
Similarly, m-health technologies challenge established concepts of
what constitutes “health information” or medically relevant informa-
tion. As explained above, m-health comprises a diverse range of devices
from self-tracking devices (sensors andmobile apps) for healthy people
who want to be aware of their eating, sleeping, exercising patterns as
well as their vital signs (heartbeat, blood pressure, etc.) to tools for pa-
tients with chronic conditions (diabetes, COPD, asthma, etc.) to help
themmanage their health. These devices collect different types of bodily
data and are integrated in different practices. In the case of apps for di-
abetes management, for example, diabetic patients can measure the
quantity of glucose in their blood through a regular or Bluetooth
glucometer that sends them to the phone, where a speciﬁc app records
readings on a logbook, shows statistics and trends, calculates the insulin
intake they have to consume offers personalised advice and educational
tip based on the patient's input, and eventually shares information with
the doctor.26 Similarly, in case of patients with asthma, commercially
available apps offer self-assessment tools as peak expiratory ﬂow rate,
symptoms, triggers andmedication diarywhose information is translat-
ed in charts that can be sharedwith GPs to change treatment.27 In these
cases, it is healthcare providers' experiences, patients' understanding of
their conditions and the medical knowledge encoded in the app's soft-
ware that renders the collected data actionable. In the case of ‘wellbeing
22 The list of the legitimate grounds allowing processing of personal data ismore restric-
tive in the case of health-related data.
23 Another example of the role of m-health in healthcare intervention is visible in the
scenarios drawn by the developers of ginger.io (https://ginger.io/). This application auto-
matically gathers and analyses data retrieved through mobile phones' sensors and
prompts health providers to take action. At themoment it is tailored to detect behavioural
changes of people with depression or other behavioural disorders. This tool translates
movement data in health-related information which is expected to support healthcare
providers to take action. Although it is not a medical device, the strong integration of such
tool into the healthcare context implies that it cannot simply be considered as a consumer
product, and a quality control is necessary.
24 Although it has been remarked also that healthcare professionals, like physicians and
pharmacists, often lack the appropriate genetics education to interpret the test results and
use the gained information todeliver better healthcare to their patients (Patrinos et al., 2013).
25 To acknowledge the different formats of clinicians' involvement in online genetic testing,
which ranges fromordering the tests on behalf of their patients to hearing about it onlywhen
their patient discloses some results to them, Barbara Prainsack and Effy Vayena introduced
the notion of beyond-the-clinic [BTC] genetics. See Prainsack and Vayena (2013).
26 Several apps for tracking and management for diabetes patients are available. See for
example, https://www.bluestardiabetes.com/ and https://itunes.apple.com/us/app/
ihealth-gluco-smart/id571576516?mt=8.
27 http://www.asthmamd.org [Accessed on December 2, 2014]. See also Huckvale et al.,
2010 for a systematic review of asthma apps.
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apps’ that are targeted at people without speciﬁc conditions, the data
detected by the app and the way it is processed, produces information
that is not clearly related to health outcomes either. In the case of
apps for measuring sleeping and exercising patterns, calories intake,
or blood oxygen level, it is unclear how the extracted data about
people's behaviour and lifestyle has a health impact and can be used
for medical purposes as the correlation between this information and
health conditions are still uncertain.
As in the case of online genetic testing, these types of self-tracking
technologies disclose a broad range of information that is not clearly
medically relevant and that involves clinical professionals very margin-
ally if at all.28 Biomedical technologies, therefore, mediate our way of
interpreting and understanding medical information in at least two
ways. First, they expand the meaning of what is health relevant data,
putting a diverse range of biological data into a health context (as it hap-
pens in the case of the Apple Inc. Health app, which integrates in the
same dashboard health and ﬁtness information from different apps
and helps consumers ‘accurately’ answer the question ‘how are you?’,
as the webpage recites29). Second, by directing their marketing efforts
towards consumers, they challenge the traditional distinction between
professionals as experts who manage a body of knowledge and make
clinical decisions on the one hand, and patients, supposedly lacking
such expertise, on the other.30 These changes in meaning challenge
our current normative structure and raise normative and political ques-
tions concerning a broad set of issues: e.g. the roles and responsibilities
of existing actors (e.g. health professionals, app developers and con-
sumers), the need to create new professional intermediary ﬁgures, the
accuracy and rational behind the interpretation of sensor-gathered
data and the role of such information and tools in (non-)medical deci-
sion making.
4. Conclusions
The strive for lifestyle change as a means for better health outcomes
has met the private interest of companies offering technological tools
for this purpose. DTC genetic tests and mobile health applications are
two examples of these ‘technologies for healthy lifestyle’. In this article
we have discussed how these exemplary technologies challenge tradi-
tional distinctions that are entrenched in our normative and regulatory
frameworks. For example, the distinction between clinical care and self-
administratedwellbeing helps to set criteria for reimbursement policies
aswell as decidingwhichdevices need special certiﬁcation because they
raise particular safety issues and which do not. Apps for wellbeing and
lifestyle blur these boundaries and require a reconsideration of the dis-
tinctions underpinning these frameworks. Such a conceptual and nor-
mative clariﬁcation is important for a number of reasons related to
regulatory challenges: 1) to establish what relevant regulation applies,
in the context of quality certiﬁcation or reimbursement policies; 2) to
deﬁne roles and responsibilities in case of liability issues; 3) to deﬁne
how these apps should enter — what the EC calls — “the main stream
of healthcare provision” (EC, 2014: p. 12).
In this paper we have discussed how regulatory debates are
unfolding in the cases of beyond-the-clinics genetic tests and m-health.
We have highlighted how in both cases the regulatory challenges are
associated with a hybrid character of both products that do not fall in
the current deﬁnition of ‘medical device’, but are also too focused on
medical practices and health domains to be considered as regular con-
sumer products. This piece makes a plea for further analysis of such a
normative ambiguity and ﬁnally offers few questions that need to be ad-
dressed in this direction.
Aﬁrst set of questions that need to be addressed concerns the hybrid
character of these products between the categories of consumer/life-
style related and healthcare/medical devices. First of all, this hybridity
needs to be unpacked: how are its multiple dimensions of meaning
and value conﬁgured in speciﬁc practices and products? Also, its impli-
cations need to be explored: for example, does this hybridity require
some system to ascertain the quality of products that do not clearly
fall in the deﬁnition of medical device and yet have a strong impact on
medical and healthcare practices? Some action has already been taken
in the direction of offering an authoritative assessment of themultitude
of available health apps: the European Directory of Health Apps31 re-
leased in October 2013 and compiled by Patient View (a UK-based re-
search, publishing and consultancy group) as well as the App Library
on NHS choice32, for example, provide guidance to people who navigate
the existing market of health apps. They also offer advice on ‘safe and
trusted apps’. If these types of assessments become more common
andwidespread— andwebelieve that they should—what kinds of bod-
ies should carry them out? And what would be the criteria for such a
body to evaluate apps as ‘safe and trusted’?
A second group of questions concerns the appropriateness of the no-
tion of ‘intended use’ by themanufacturer as a criterion to assign a prod-
uct the status of medical device. Should we abandon this criterion and
discuss instead the ‘imagined purpose’ as deﬁned by users? If the regu-
latory goal is to protect users from harm, then the benchmark must be
the actual use of a tool or technology, and not how the manufacturer
or provider intends it to be used. At the same time, looking at actual
use entails signiﬁcant challenges regarding its operationalisation. Espe-
cially for market approval, how can actual use be assessed before a tool
or device has been released? Would representative samples of ‘test
users’ be required whose actual use could determine the category
under which a new tool or device would be subsumed? In this way dif-
ferent rules would apply if I say that my purpose is to knowmore about
my ancestors or to knowmore about my health. Furthermore, the por-
table character of mobile health devices, i.e. the fact that they can be
easily and discretely carried around by individuals, makes the physical
and social context relevant for the deﬁnition of what is medical and
what is not. When these health devices move ‘beyond the clinic’, how
to take into account the always varying social factors that make the col-
lected data and suggested action health (or medically) relevant or not?
Finally, it is often unclear who the experts for the interpretation of
particular health-relevant data are. For example, for online genetic
tests, general practitioners — who often have not been trained exten-
sively in genetics — may not be the best experts to entrust with this.
Whowill ﬁll this ‘interpretive vacuum’ (see also Beckmann, 2014)? Au-
thors have discussed the trends towards personalised medicine and the
(bio)medicalisation of everyday life (e.g. Clarke et al., 2010). However,
new technologies and practices provide a wealth of data on individuals
at various stages of health and disease that go beyond people's biologi-
cal make up but include information also on people's interests, hobbies,
priorities and lifestyle. Should we start to explore the trend towards
“lifestylisation” of healthcare,33 in which treatments are not only
personalised to the person's genetic makeup but also to the individual's
lifestyle?
28 Interestingly, business models of health and wellbeing apps are very diverse at the
moment and are directed not only towards individual consumers, but also GP, insurance
companies, public services, employees (see also: http://medcitynews.com/2014/04/
mobile-health-business-models-still-work-progress/ [Accessed on January 7, 2015]).
29 See https://www.apple.com/ios/whats-new/health/ [Accessed on January 7, 2015].
30 This distinction is currently challenged from different fronts. Besides the type of bio-
medical technological and scientiﬁc innovation discussed here, there are several types of
service innovation in public health programmes that aims at giving a central role to pa-
tients. The Expert Patients Programme established by the NHS inUK in 2007 aims at offer-
ing self management courses to people living with chronic disorders http://www.nhs.uk/
NHSEngland/AboutNHSservices/doctors/Pages/expert-patients-programme.aspx
(Accessed on December 17, 2014).
31 Available at http://www.patient-view.com/-bull-directories.html.
32 Available at http://apps.nhs.uk/.
33 See also O'Brien (1995) who refers to “styled” health as an on-going trend since the
1980s in opposition to the medicalisation of everyday life and Paula Saukko contribution
at the European Association for the Study of Science and Technology: “Contestation be-
tween evidence based medicine and lifestylisation of medicine: the case of online genetic
testing” (EASST conference, Torun Poland, 17–19 September 2014).
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